Vical Incorporated (VICL)
-NasdaqGS | Prev Close: | 3.51 |
|---|
| Open: | N/A |
|---|
| Bid: | 3.50 x 100 |
|---|
| Ask: | 5.66 x 100 |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | 1.22 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.61 - 4.74 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 660,543 |
|---|
| Market Cap: | 303.43M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Interesting VICL Put And Call For Julyat TheStreet(Mon, May 20)
- VICAL INC FinancialsEDGAR Online Financials(Fri, May 17)
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharmaat TheStreet(Fri, May 17)
- Vical's CEO Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)at Seeking Alpha(Tue, May 14)
- Short Interest In Vical Moves 21.2% Higherat TheStreet(Fri, May 10)
- VICAL INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Vical's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Vical Earnings: Here’s Why Investors are Happy Nowat Wall St. Cheat Sheet(Thu, May 9)
- Q1 2013 Vical Inc. Earnings Release - Before Market OpenCCBN(Thu, May 9)
- Vical Reports First Quarter 2013 Financial Results and Progress in Key Development ProgramsGlobeNewswire(Thu, May 9)
- VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, May 8)
- Galena: Improving Cancer Vaccines for the Futureat Motley Fool(Tue, May 7)
- Vical to Present at May Investor ConferencesGlobeNewswire(Tue, May 7)
- Vaxfectin(R) Enhances Preclinical Immune Responses to Baxter's Cell Culture-Derived Influenza VaccinesGlobeNewswire(Mon, May 6)
- Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trialat Seeking Alpha(Fri, May 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 39.75 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.46 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.11 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
View More